Evidence map›Paper›PMID 40193849›Full record

ReviewACS nano2025

Design Considerations for Organ-Selective Nanoparticles.

Min-Jun Baek, Won Hur, Satoshi Kashiwagi, Hak Soo Choi

Abstract readReview
In one paragraph

Review in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Review
  3. Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Kupffer Cell Capture-Evading Modifiable Sub-20 nm Lipid Nanodisc-BasedJournal of the American Chemical Society · 2026
    Article
  9. Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Min-Jun BaekGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.
Won HurGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0002-4092-0165
Satoshi KashiwagiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0001-8910-3257
Hak Soo ChoiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0002-7982-6483

Funding

Targeting parathyroid glands with novel fluorophores for intraoperative imagingR01CA280968 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Michael Bouvet, Maged M Henary · 2023 to 2026
$2.8M
NCI NIH HHS R01 CA280968
6 · The paper itself

Abstract

Nanoparticles (NPs) have been extensively researched for targeted diagnostic imaging and drug delivery, yet their clinical translation remains limited, with only a few achieving Food and Drug Administration approval. This limited success is primarily due to challenges in achieving precise organ- or tissue-specific targeting, which arise from off-target tissue accumulation and suboptimal clearance profiles. Herein we examine the critical role of physicochemical properties, including size, surface charge, shape, elasticity, hardness, and density, in governing the biodistribution, targetability, and clearance of NPs. We highlight recent advancements in engineering NPs for targeted imaging and drug delivery, showcasing both significant progress and the remaining challenges in the field of nanomedicine. Additionally, we discuss emerging tools and technologies that are being developed to address these challenges. Based on recent insights from materials science, biomedical engineering, computational biology, and clinical research, we propose key design considerations for next-generation nanomedicines with enhanced organ selectivity.

Indexed as

NanoparticlesAnimalsDrug Delivery SystemsHumansNanomedicineOrgan SpecificityTissue DistributionArtificial intelligenceBiodistributionClinical applicationsExcretionHigh-throughput screeningMachine learningNanoparticlesPhysicochemical properties

Identifiers

PMID40193849
PMCPMC12962755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.